New drug access for low blood sugar after Weight-Loss surgery
NCT ID NCT07582874
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers avexitide to people with post-bariatric hypoglycemia (dangerously low blood sugar) after Roux-en-Y gastric bypass. Eligible patients include those who completed the LUCIDITY trial or other avexitide studies. Participants receive a daily injection before their first meal, and safety is monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Avexitide (a drug injected under the skin once daily before the first meal)
What this could lead to
If it works, this could offer ongoing symptom control for people with dangerously low blood sugar after weight-loss surgery.
What could go wrong
This is an expanded access program, not a formal trial, so evidence is limited. The drug may not work for everyone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-BARIATRIC HYPOGLYCEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Diabetes and Glandular Disease Clinic
AVAILABLESan Antonio, Texas, 78229-4801, United States